BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951. [PMID: 24797281 DOI: 10.1002/lt.23904] [Cited by in Crossref: 145] [Cited by in F6Publishing: 128] [Article Influence: 20.7] [Reference Citation Analysis]
Number Citing Articles
1 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
2 Chan MY, She WH, Dai WC, Tsang SHY, Chok KSH, Chan ACY, Fung J, Lo CM, Cheung TT. Prognostic value of preoperative alpha-fetoprotein (AFP) level in patients receiving curative hepatectomy- an analysis of 1,182 patients in Hong Kong. Transl Gastroenterol Hepatol 2019;4:52. [PMID: 31463411 DOI: 10.21037/tgh.2019.06.07] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
3 Mehta N, Dodge JL, Roberts JP, Yao FY. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol 2021;74:829-37. [PMID: 33188904 DOI: 10.1016/j.jhep.2020.10.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Clark P. Serum markers for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2016;8:29-33. [PMID: 31041059 DOI: 10.1002/cld.565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
5 Mahmud N, Shaked A, Olthoff KM, Goldberg DS. Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease. Liver Transpl 2019;25:388-98. [PMID: 30362249 DOI: 10.1002/lt.25363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Harding-Theobald E, Yao FYK, Mehta N. Neutrophil-to-Lymphocyte Ratio Predicts High-Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2021;27:818-29. [PMID: 33570786 DOI: 10.1002/lt.26010] [Reference Citation Analysis]
7 Ormiston WEL, Yarmohammadi H, Lobaugh S, Schilsky J, Katz SS, LaGratta M, Velayati S, Zheng J, Capanu M, Do RKG. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization. Abdom Radiol (NY) 2021;46:3738-47. [PMID: 32968863 DOI: 10.1007/s00261-020-02775-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang LY, Zheng SS. Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation. J Zhejiang Univ Sci B 2018;19:497-504. [PMID: 29971988 DOI: 10.1631/jzus.B1700156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
9 Nadalin S, Genedy L, Königsrainer A. Liver Living Donation for Cancer Patients: Benefits, Risks, Justification. Recent Results Cancer Res 2021;218:135-48. [PMID: 34019167 DOI: 10.1007/978-3-030-63749-1_10] [Reference Citation Analysis]
10 Kalra A, Biggins SW. New paradigms for organ allocation and distribution in liver transplantation. Current Opinion in Gastroenterology 2018;34:123-31. [DOI: 10.1097/mog.0000000000000434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 de la Fuente S, Citores MJ, Lucena JL, Muñoz P, Cuervas-Mons V. TLR9-1486C/T polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation. Biomark Med 2019;13:995-1004. [PMID: 31317790 DOI: 10.2217/bmm-2019-0030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Dong J, Zhu Y, Ma F, Ren Y, Lu J, Wang Z, Qin L, Wu R, Lv Y. Conditional disease-free survival after liver transplantation for hepatocellular carcinoma: A two-center experience. Medicine (Baltimore) 2016;95:e4383. [PMID: 27495049 DOI: 10.1097/MD.0000000000004383] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
14 Ponziani FR, Spinelli I, Rinninella E, Cerrito L, Saviano A, Avolio AW, Basso M, Miele L, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giuliante F, Vecchio FM, Agnes S, Addolorato G, Siciliano M, Rapaccini GL, Grieco A, Gasbarrini A, Pompili M. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World J Hepatol. 2017;9:1322-1331. [PMID: 29359015 DOI: 10.4254/wjh.v9.i36.1322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol. 2016;22:232-252. [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
16 Wang P, Song W, Li H, Wang C, Shi B, Guo W, Zhong L. Association between donor and recipient smoothened gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population. Tumour Biol 2015;36:7807-15. [PMID: 25944162 DOI: 10.1007/s13277-015-3370-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
17 Kwong A, Mehta N. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis 2021;25:19-33. [PMID: 33978578 DOI: 10.1016/j.cld.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lai Q, Inostroza M, Rico Juri JM, Goffette P, Lerut J. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer. HPB (Oxford) 2015;17:1085-95. [PMID: 26373980 DOI: 10.1111/hpb.12486] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
19 Zhu Z. Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:498-502. [PMID: 28124007 DOI: 10.21037/hbsn.2016.12.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Mazzotta AD, Pascale A, Cano L, Rosmorduc O, Allard MA, Sa Cunha A, Adam R, Cherqui D, Vibert E, Golse N. Number of hepatocellular carcinoma nodules in patients listed for liver transplantation within alpha-fetoprotein score: a new prognostic risk factor. Transpl Int 2021;34:954-63. [PMID: 33660346 DOI: 10.1111/tri.13858] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK Jr, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968-1977. [PMID: 25689978 DOI: 10.1002/hep.27752] [Cited by in Crossref: 217] [Cited by in F6Publishing: 160] [Article Influence: 36.2] [Reference Citation Analysis]
22 Lysy PA, Smets F, Sibille C, Najimi M, Sokal EM. Human skin fibroblasts: From mesodermal to hepatocyte-like differentiation. Hepatology. 2007;46:1574-1585. [PMID: 17969047 DOI: 10.1002/hep.28139] [Cited by in Crossref: 82] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
23 Ma KW, Chan ACY, She BWH, Chok KSH, Cheung TT, Dai JWC, Fung JYY, Lo CM. Changing Paradigm in the Surgical Management of Hepatocellular Carcinoma With Salvage Transplantation. Transplant Proc 2018;50:1087-93. [PMID: 29731072 DOI: 10.1016/j.transproceed.2018.01.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Seminars in Diagnostic Pathology 2017;34:153-9. [DOI: 10.1053/j.semdp.2016.12.011] [Cited by in Crossref: 153] [Cited by in F6Publishing: 136] [Article Influence: 38.3] [Reference Citation Analysis]
25 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
26 Zhang T, Liu Y, Peng X, Fan J, Peng Z. Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation. Dis Markers 2017;2017:1754696. [PMID: 29162948 DOI: 10.1155/2017/1754696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Machaca MP, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Fauda M, McCormack L, Gadano A, Boin IS, García JHP, Silva M. Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study. Ann Hepatol 2018;17:256-67. [PMID: 29469048 DOI: 10.5604/01.3001.0010.8648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant 2019;19:2210-8. [PMID: 30861298 DOI: 10.1111/ajt.15353] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
29 Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver Transplantation Beyond Milan Criteria. J Clin Transl Hepatol 2020;8:69-75. [PMID: 32274347 DOI: 10.14218/JCTH.2019.00050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
30 Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019;11:50-64. [PMID: 30705718 DOI: 10.4254/wjh.v11.i1.50] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
31 Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018;24:327-329. [PMID: 29351366 DOI: 10.1002/lt.25017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chu KK, Wong KH, Chok KS. Expanding Indications for Liver Transplant: Tumor and Patient Factors. Gut Liver 2021;15:19-30. [PMID: 32102130 DOI: 10.5009/gnl19265] [Reference Citation Analysis]
33 Halazun KJ, Tabrizian P, Najjar M, Florman S, Schwartz M, Michelassi F, Samstein B, Brown RS, Emond JC, Busuttil RW, Agopian VG. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg. 2018;268:690-699. [PMID: 30048307 DOI: 10.1097/sla.0000000000002964] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
34 Lai Q, Lerut J. α-Fetoprotein and hepatocellular cancer recurrence: a paradigm of the chaos theory. Liver Transpl. 2014;20:1283. [PMID: 25060782 DOI: 10.1002/lt.23962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
35 Zhao T, Jia L, Li J, Ma C, Wu J, Shen J, Dang L, Zhu B, Li P, Zhi Y, Lan R, Xu Y, Hao Z, Chai Y, Li Q, Hu L, Sun S. Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations. Front Oncol 2020;10:496. [PMID: 32426269 DOI: 10.3389/fonc.2020.00496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
36 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
37 Irtan S, Barbier L, Francoz C, Dondéro F, Durand F, Belghiti J. Liver transplantation for hepatocellular carcinoma: is zero recurrence theoretically possible? Hepatobiliary & Pancreatic Diseases International 2016;15:147-51. [DOI: 10.1016/s1499-3872(16)60069-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
38 Feng J, Zhu R, Feng D, Yu L, Zhao D, Wu J, Yuan C, Chen J, Zhang Y, Zheng X. Prediction of Early Recurrence of Solitary Hepatocellular Carcinoma after Orthotopic Liver Transplantation. Sci Rep 2019;9:15855. [PMID: 31676847 DOI: 10.1038/s41598-019-52427-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Feng J, Wu J, Zhu R, Feng D, Yu L, Zhang Y, Bu D, Li C, Zhou Y, Si L, Liu Y, Liang Z, Xu J, Wu T. Simple Risk Score for Prediction of Early Recurrence of Hepatocellular Carcinoma within the Milan Criteria after Orthotopic Liver Transplantation. Sci Rep. 2017;7:44036. [PMID: 28276470 DOI: 10.1038/srep44036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
40 Ma KW, She WH, Chan ACY, Cheung TT, Fung JYY, Dai WC, Lo CM, Chok KSH. Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population. World J Gastrointest Oncol 2019;11:322-34. [PMID: 31040897 DOI: 10.4251/wjgo.v11.i4.322] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Wang LY, Zheng SS, Xu X, Wang WL, Wu J, Zhang M, Shen Y, Yan S, Xie HY, Chen XH, Jiang TA, Chen F. A score model for predicting post-liver transplantation survival in HBV cirrhosis-related hepatocellular carcinoma recipients: a single center 5-year experience. Hepatobiliary Pancreat Dis Int 2015;14:43-9. [PMID: 25655289 DOI: 10.1016/s1499-3872(15)60335-6] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
42 Elshamy M, Aucejo F, Menon KV, Eghtesad B. Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria. World J Hepatol 2016;8:874-80. [PMID: 27478537 DOI: 10.4254/wjh.v8.i21.874] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
43 Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken) 2019;13:20-5. [PMID: 31168361 DOI: 10.1002/cld.793] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
44 Lai Q, Iesari S, Melandro F, Mennini G, Rossi M, Lerut J. The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. Transl Gastroenterol Hepatol 2017;2:72. [PMID: 29034345 DOI: 10.21037/tgh.2017.09.05] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
45 Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18:1206-1213. [PMID: 29068145 DOI: 10.1111/ajt.14549] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
46 Lai Q, Nicolini D, Inostroza Nunez M, Iesari S, Goffette P, Agostini A, Giovagnoni A, Vivarelli M, Lerut J. A Novel Prognostic Index in Patients With Hepatocellular Cancer Waiting for Liver Transplantation: Time–Radiological-response–Alpha-fetoprotein–INflammation (TRAIN) Score. Annals of Surgery 2016;264:787-96. [DOI: 10.1097/sla.0000000000001881] [Cited by in Crossref: 48] [Cited by in F6Publishing: 23] [Article Influence: 9.6] [Reference Citation Analysis]
47 Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit? Transl Gastroenterol Hepatol. 2017;2:106. [PMID: 29354763 DOI: 10.21037/tgh.2017.11.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
48 Liao C, An J, Yi S, Tan Z, Wang H, Li H, Guan X, Liu J, Wang Q. FUT8 and Protein Core Fucosylation in Tumours: From Diagnosis to Treatment. J Cancer 2021;12:4109-20. [PMID: 34093814 DOI: 10.7150/jca.58268] [Reference Citation Analysis]
49 Charriere B, Muscari F, Maulat C, Bournet B, Bonnet D, Bureau C, Otal P, Peron J, Suc B. Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings: Treatment of Hepatocellular Carcinoma. J Surg Oncol 2017;115:330-6. [DOI: 10.1002/jso.24500] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
50 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016;8:58-68. [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
51 Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA. LI.CA study group. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Med. 2016;13:e1002006. [PMID: 27116206 DOI: 10.1371/journal.pmed.1002006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 12.8] [Reference Citation Analysis]
52 Schraiber LDS, de Mattos AA, Zanotelli ML, Cantisani GPC, Brandão ABM, Marroni CA, Kiss G, Ernani L, Marcon PDS. Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma. Medicine (Baltimore) 2016;95:e2478. [PMID: 26817881 DOI: 10.1097/MD.0000000000002478] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
53 Alver SK, Lorenz DJ, Washburn K, Marvin MR, Brock GN. Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry. Transpl Int 2017;30:1098-109. [PMID: 28403575 DOI: 10.1111/tri.12967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
54 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015;7:649-61. [PMID: 25866602 DOI: 10.4254/wjh.v7.i4.649] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
55 Firl DJ, Kimura S, Mcvey J, Hashimoto K, Yeh H, Miller CM, Markmann JF, Sasaki K, Aucejo FN. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Hepatology 2018;68:1448-58. [DOI: 10.1002/hep.29907] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
56 Piñero F, Tisi Baña M, de Ataide EC, Hoyos Duque S, Marciano S, Varón A, Anders M, Zerega A, Menéndez J, Zapata R, Muñoz L, Padilla Machaca M, Soza A, McCormack L, Poniachik J, Podestá LG, Gadano A, Boin IS, Duvoux C, Silva M; Latin American Liver Research, Education and Awareness Network (LALREAN). Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int 2016;36:1657-67. [PMID: 27169841 DOI: 10.1111/liv.13159] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
57 Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64:2077-2088. [PMID: 27178646 DOI: 10.1002/hep.28643] [Cited by in Crossref: 148] [Cited by in F6Publishing: 127] [Article Influence: 29.6] [Reference Citation Analysis]
58 Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262-276. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]
59 Brusset B, Dumortier J, Cherqui D, Pageaux GP, Boleslawski E, Chapron L, Quesada JL, Radenne S, Samuel D, Navarro F, Dharancy S, Decaens T. Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model. Cancers (Basel) 2021;13:2480. [PMID: 34069594 DOI: 10.3390/cancers13102480] [Reference Citation Analysis]
60 Vitale A, Farinati F, Burra P, Trevisani F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Chiaramonte M, Spolverato G, Cillo U; for the Italian Liver Cancer group. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor: Utility-Based Patient Selection. Liver Transpl 2015;21:1250-8. [DOI: 10.1002/lt.24214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
61 Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-Fetoprotein Slope; 7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018;102:816-822. [PMID: 29505494 DOI: 10.1097/tp.0000000000002094] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
62 Yang PC, Ho CM, Hu RH, Ho MC, Wu YM, Lee PH. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol 2016;8:1309-17. [PMID: 27872682 DOI: 10.4254/wjh.v8.i31.1309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
63 Kim B, Kahn J, Terrault NA. Liver transplantation as therapy for hepatocellular carcinoma. Liver Int 2020;40 Suppl 1:116-21. [PMID: 32077598 DOI: 10.1111/liv.14346] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
64 Al-Ameri AAM, Wei X, Lin L, Shao Z, Guo H, Xie H, Zhou L, Zheng S, Xu X. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation. BMC Cancer. 2019;19:1136. [PMID: 31752756 DOI: 10.1186/s12885-019-6343-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
65 Mehta NJ, Celik AD, Peters MG. Screening for hepatocellular carcinoma: What is missing? Hepatol Commun 2017;1:18-22. [PMID: 29404430 DOI: 10.1002/hep4.1014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
66 Pardo F, Pons JA, Briceño J. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. Gastroenterología y Hepatología 2015;38:600-18. [DOI: 10.1016/j.gastrohep.2015.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Ashokachakkaravarthy K, Pottakkat B. Mitotic quiescence in hepatic cancer stem cells: An incognito mode. Oncol Rev 2020;14:452. [PMID: 32153726 DOI: 10.4081/oncol.2020.452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Yoo T, Lee KW, Yi NJ, Choi YR, Kim H, Suh SW, Jeong JH, Lee JM, Suh KS. Peri-Transplant Change in AFP Level: a Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation. J Korean Med Sci 2016;31:1049-54. [PMID: 27366001 DOI: 10.3346/jkms.2016.31.7.1049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
69 Grąt M, Stypułkowski J, Morawski M, Wronka KM, Wasilewicz M, Lewandowski Z, Grąt K, Wójcik Z, Patkowski W, Zieniewicz K. Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation. Ann Surg 2020;271:1124-31. [PMID: 30601254 DOI: 10.1097/SLA.0000000000003176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
70 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
71 Viveiros A, Zoller H, Finkenstedt A. Hepatocellular carcinoma: when is liver transplantation oncologically futile? Transl Gastroenterol Hepatol 2017;2:63. [PMID: 28815223 DOI: 10.21037/tgh.2017.07.03] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
72 Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: A comprehensive review. World J Hepatol. 2015;7:2648-2663. [PMID: 26609342 DOI: 10.4254/wjh.v7.i26.2648] [Cited by in Crossref: 115] [Cited by in F6Publishing: 104] [Article Influence: 19.2] [Reference Citation Analysis]
73 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
74 Chuang YH, Ou HY, Yu CY, Chen CL, Weng CC, Tsang LL, Hsu HW, Lim WX, Huang TL, Cheng YF. Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation. Cancer Imaging 2019;19:74. [PMID: 31730015 DOI: 10.1186/s40644-019-0264-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology 2020;71:943-54. [PMID: 31344273 DOI: 10.1002/hep.30879] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 20.5] [Reference Citation Analysis]
76 Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, Uemoto S, Kokudo N, Hasegawa K, Ohdan H, Egawa H, Furukawa H, Todo S;  Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. Transpl Int. 2019;32:356-368. [PMID: 30556935 DOI: 10.1111/tri.13391] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
77 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 132] [Article Influence: 36.5] [Reference Citation Analysis]
78 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 317] [Article Influence: 121.7] [Reference Citation Analysis]
79 Morris PD, Laurence JM, Yeo D, Crawford M, Strasser SI, Mccaughan GW, Sandroussi C. Can response to locoregional therapy help predict longterm survival after liver transplantation for hepatocellular carcinoma? A systematic review: MORRIS et al. Liver Transpl 2017;23:375-85. [DOI: 10.1002/lt.24689] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
80 Tanaka T, Kurosaki M, Lilly LB, Izumi N, Sherman M. Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis. J Surg Oncol 2015;112:72-9. [PMID: 26032085 DOI: 10.1002/jso.23944] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
81 Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019;69:1193-205. [PMID: 30548884 DOI: 10.1002/hep.30413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
82 Foerster F, Mittler J, Darstein F, Heise M, Marquardt JU, Wörns MA, Weinmann A, Sälter L, Hoppe-Lotichius M, Heinrich S, Kloeckner R, Pitton MB, Schattenberg JM, Sprinzl MF, Düber C, Otto G, Lang H, Galle PR, Zimmermann T. Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. Eur J Intern Med 2018;55:57-65. [PMID: 29859798 DOI: 10.1016/j.ejim.2018.05.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
83 Saberi B, Garonzik-Wang J, Ma M, Ajayi T, Kim A, Luu H, Jakhete N, Pustavoitau A, Anders RA, Georgiades C, Kamel I, Ottmann S, Philosophe B, Cameron AM, Gurakar A. Accuracy of Milan, University of California San Francisco, and Up-To-7 Criteria in Predicting Tumor Recurrence Following Deceased-Donor Liver Transplant in Patients With Hepatocellular Carcinoma. Exp Clin Transplant 2020;18:463-9. [PMID: 30084757 DOI: 10.6002/ect.2017.0288] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
84 Goldberg D, Mantero A, Newcomb C, Delgado C, Forde KA, Kaplan DE, John B, Nuchovich N, Dominguez B, Emanuel E, Reese PP. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. J Hepatol. 2021;74:1398-1406. [PMID: 33453328 DOI: 10.1016/j.jhep.2020.12.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
85 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
86 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015;7:362-76. [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
87 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Sherif RN, Abdellatif H, Hazem N, Ebrahim NA, Saleh D, Shiha G, Eltahry H, Botros KG, Gabr OM. Effect of human umbilical cord blood derived CD34 + hematopoietic stem cell on the expression of Wnt4 and P53 genes in a rat model of hepatocellular carcinoma. Tissue and Cell 2018;50:125-32. [DOI: 10.1016/j.tice.2018.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Zhang W, Lai SL, Chen J, Xie D, Wu FX, Jin GQ, Su DK. Validated preoperative computed tomography risk estimation for postoperative hepatocellular carcinoma recurrence. World J Gastroenterol 2017;23:6467-73. [PMID: 29085196 DOI: 10.3748/wjg.v23.i35.6467] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
90 Sapisochin G, Goldaracena N, Astete S, Laurence JM, Davidson D, Rafael E, Castells L, Sandroussi C, Bilbao I, Dopazo C, Grant DR, Lázaro JL, Caralt M, Ghanekar A, McGilvray ID, Lilly L, Cattral MS, Selzner M, Charco R, Greig PD. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series. Ann Surg Oncol 2015;22:2286-94. [PMID: 25472651 DOI: 10.1245/s10434-014-4273-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
91 Lai Q, Levi Sandri GB, Lerut J. Selection tool alpha-fetoprotein for patients waiting for liver transplantation: How to easily manage a fractal algorithm. World J Hepatol. 2015;7:1899-1904. [PMID: 26244064 DOI: 10.4254/wjh.v7.i15.1899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
92 Kow AWC. Transplantation vs liver resection in patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2019;4:33. [PMID: 31231700 DOI: 10.21037/tgh.2019.05.06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
93 Charrière B, Maulat C, Suc B, Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J Hepatol 2016;8:881-90. [PMID: 27478538 DOI: 10.4254/wjh.v8.i21.881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
94 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
95 Welling TH, Eddinger K, Carrier K, Zhu D, Kleaveland T, Moore DE, Schaubel DE, Abt PL. Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation. Liver Transpl. 2018;24:1233-1242. [PMID: 29729113 DOI: 10.1002/lt.25194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
96 Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology. 2015;62:158-165. [PMID: 25777590 DOI: 10.1002/hep.27787] [Cited by in Crossref: 135] [Cited by in F6Publishing: 117] [Article Influence: 22.5] [Reference Citation Analysis]
97 Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol 2018;16:955-64. [PMID: 29175528 DOI: 10.1016/j.cgh.2017.11.037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
98 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. WJCO 2021;12:623-45. [DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
99 Yoon JH, Lee WJ, Kim SM, Kim KT, Cho SB, Kim HJ, Ko YS, Kook HY, Jun CH, Choi SK, Kim BS, Cho SY, You HS, Lee Y, Son S. Simple parameters predicting extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Sci Rep 2021;11:12984. [PMID: 34155324 DOI: 10.1038/s41598-021-92503-6] [Reference Citation Analysis]
100 El-Fattah MA. Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA. Indian J Gastroenterol. 2017;36:117-125. [PMID: 28194604 DOI: 10.1007/s12664-017-0732-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
101 Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Current Opinion in Organ Transplantation 2016;21:91-8. [DOI: 10.1097/mot.0000000000000282] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.6] [Reference Citation Analysis]
102 Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017;101:2071-2078. [PMID: 28353492 DOI: 10.1097/tp.0000000000001752] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
103 Li X, Huang L, Leng X. Analysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation. J Cancer Res Clin Oncol 2018;144:2465-74. [PMID: 30259149 DOI: 10.1007/s00432-018-2756-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
104 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
105 Xue J, Cao Z, Cheng Y, Wang J, Liu Y, Yang R, Li H, Jiang W, Li G, Zhao W, Zhang X. Acetylation of alpha-fetoprotein promotes hepatocellular carcinoma progression. Cancer Lett 2020;471:12-26. [PMID: 31811908 DOI: 10.1016/j.canlet.2019.11.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
106 Pardo F, Pons JA, Briceño J. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. Cirugía Española 2015;93:619-37. [DOI: 10.1016/j.ciresp.2015.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
107 Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, Miglioresi L, Vitale A, Vennarecci G, Ambrosio CD, Burra P, Di Benedetto F, Fagiuoli S, Colasanti M, Maria Ettorre G, Andreoli A, Cillo U, Laurent A, Katsahian S, Audureau E, Roudot-Thoraval F, Duvoux C. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66:552-559. [PMID: 27899297 DOI: 10.1016/j.jhep.2016.10.038] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 15.0] [Reference Citation Analysis]
108 Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TL, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 2015;7:1460-83. [PMID: 26085907 DOI: 10.4254/wjh.v7.i11.1460] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
109 Gurakar A, Ma M, Garonzik-wang J, Kim A, Anders RA, Oshima K, Georgiades C, Gurakar M, Ottmann S, Cameron AM, Philosophe B, Saberi B. Clinicopathological Distinction of Low-AFP-Secreting vs. High-AFP-Secreting Hepatocellular Carcinomas. Annals of Hepatology 2018;17:1052-66. [DOI: 10.5604/01.3001.0012.7206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
110 Bhatti ABH, Naqvi W, Khan NY, Zia HH, Dar FS, Khan ZA, Rana A. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion. J Cancer Res Clin Oncol 2021. [PMID: 34117916 DOI: 10.1007/s00432-021-03665-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Chapman WC, Garcia-Aroz S, Vachharajani N, Fowler K, Saad N, Lin Y, Wellen J, Tan B, Khan AS, Doyle MB. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. J Am Coll Surg. 2017;224:610-621. [PMID: 28069527 DOI: 10.1016/j.jamcollsurg.2016.12.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
112 Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. World J Hepatol 2019;11:261-72. [PMID: 30967904 DOI: 10.4254/wjh.v11.i3.261] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
113 Song SS, Yuan PF, Li PP, Wu HX, Ni WJ, Lu JT, Wei W. Protective Effects of Total Glucosides of Paeony on N-nitrosodiethylamine-induced Hepatocellular Carcinoma in Rats via Down-regulation of Regulatory B Cells. Immunological Investigations 2015;44:521-35. [DOI: 10.3109/08820139.2015.1043668] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
114 Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017;3:493-500. [PMID: 27838698 DOI: 10.1001/jamaoncol.2016.5116] [Cited by in Crossref: 111] [Cited by in F6Publishing: 95] [Article Influence: 27.8] [Reference Citation Analysis]
115 Ince V, Akbulut S, Otan E, Ersan V, Karakas S, Sahin TT, Carr BI, Baskiran A, Samdanci E, Bag HG, Koc C, Usta S, Ozdemir F, Barut B, Gonultas F, Sarici B, Kutluturk K, Dogan MS, Ozgor D, Dikilitas M, Harputluoglu M, Aladag M, Kutlu R, Varol I, Dirican A, Aydin C, Isik B, Ara C, Kayaalp C, Emre S, Yilmaz S. Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria. J Gastrointest Cancer. 2020;51:998-1005. [PMID: 32519232 DOI: 10.1007/s12029-020-00424-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
116 Lin CC, Chen CL. Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes. Hepatobiliary Surg Nutr 2016;5:415-21. [PMID: 27826556 DOI: 10.21037/hbsn.2016.08.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
117 Abreu P, Gorgen A, Griffiths C, Ivanics T, Sapisochin G. Downstaging and Expanded Criteria Hepatocellular Carcinoma Liver Transplantation. Curr Hepatology Rep 2019;18:400-7. [DOI: 10.1007/s11901-019-00492-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
118 Rudnick SR, Russo MW. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2018;12:265-75. [PMID: 29231769 DOI: 10.1080/17474124.2018.1417035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
119 Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220:416-427. [PMID: 25690672 DOI: 10.1016/j.jamcollsurg.2014.12.025] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 18.9] [Reference Citation Analysis]
120 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
121 Yao FY, Hameed B, Mehta N, Roberts JP. Response to letter to the editors. Liver Transpl. 2014;20:1285. [PMID: 25155484 DOI: 10.1002/lt.23982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
122 Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, Manas D, Shah T, Newsome PN, Reeves H, Shetty S. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73-81. [PMID: 27634970 DOI: 10.1093/qjmed/hcw151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
123 Halazun KJ, Rosenblatt RE, Mehta N, Lai Q, Hajifathalian K, Gorgen A, Brar G, Sasaki K, Doyle MBM, Tabrizian P, Agopian VG, Najjar M, Ivanics T, Samstein B, Brown RS Jr, Emond JC, Yao F, Lerut J, Rossi M, Mennini G, Iesari S, Finkenstedt A, Schaefer B, Mittler J, Hoppe-Lotichius M, Quintini C, Aucejo F, Chapman W, Sapisochin G. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA Surg 2021;156:559-67. [PMID: 33950167 DOI: 10.1001/jamasurg.2021.0954] [Reference Citation Analysis]
124 Pommergaard HC, Burcharth J, Rosenberg J, Rasmussen A. Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2016;30:171-177. [PMID: 27118303 DOI: 10.1016/j.trre.2016.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
125 Chang W, He W, Li PP, Song SS, Yuan PF, Lu JT, Wei W. Protective effects of Celastrol on diethylnitrosamine-induced hepatocellular carcinoma in rats and its mechanisms. Eur J Pharmacol 2016;784:173-80. [PMID: 27181068 DOI: 10.1016/j.ejphar.2016.04.045] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
126 Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology. 2016;63:1707-1717. [PMID: 26703761 DOI: 10.1002/hep.28420] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 13.2] [Reference Citation Analysis]
127 Montalvá EM, Cantos M, Boscà A, Rubín A, Vinaixa C, Granero P, Maupoey J, López-Andújar R. Prognostic Value of Pre-transplantation Serum Alpha-Fetoprotein Levels in Hepatocellular Carcinoma Recurrence. Transplant Proc 2016;48:2966-8. [PMID: 27932120 DOI: 10.1016/j.transproceed.2016.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
128 Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42. [DOI: 10.1097/tp.0000000000003174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 16.0] [Reference Citation Analysis]